Eli Lilly to pay $62M to settle Zyprexa marketing charges

Pharmaceutical company Eli Lilly has agreed $62 million to 33 states to settle charges that it marketed anti-psychotic Zyprexa for unapproved uses. It's not clear what effect the agreement will have on sales of Zyprexa, which was Lilly's best-selling product in 2005 with sales of $4.2 billion.

The settlement closes an 18-month investigation by the attorneys general of Illinois and Oregon, who concluded that Lilly marketed Zyprexa as a treatment for dementia and milder forms of schizophrenia and mania, as well as marketing it for use in children. The FDA has only approved it as a treat for schizophrenia and mania associated with bipolar disorder in adults.

Under the terms of the settlement, Lilly will have to follow ethical marketing guidelines under which medical staff, rather than marketers, must write medical letters sent to doctors.

To learn more about the settlement:
- read this Kaiser Daily Health Policy Report item

Related Articles:
Schering fined $435M for off-label marketing
Lilly accused of promoting off-label Zyprexa use
Cephalon settlement requires physician payments to be disclosed

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.